NightstaRx Ltd (Nightstar), a biopharmaceutical company spun out from the University of Oxford specialising in developing gene therapies for inherited retinal dystrophies, has announced that it has completed a $35 million (£23.2 million) funding round. The round was led by New Enterprise Associates (NEA), one of the world’s leading venture capital firms.
Nightstar’s lead programme is a gene therapy for an inherited form of progressive blindness, choroideremia, developed by Professor Robert MacLaren at Oxford’s Nuffield Laboratory of Ophthalmology, part of the Nuffield Department of Clinical Neurosciences.